INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 3

Application No. 10/063,718

Filing Date May 8, 2002

First Named Inventor Goddard, et al.

Art Unit 1647

Examiner Sandra L. Wegert

Attorney Docket No. GNE.3230R1C149

• _				U.S. PATENT	DOCUMENTS	
Exan		Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
T	W	1	6,025,156	02-15-2000	Gwynn, et al.	
		2	6,124,433	09-26-2000	Falb, et al.	
		3	6,156,500	12-05-2000	Falb, Dean	_
		4	6,162,604	12-19-2000	Jacob, Chaim O.	
		5	6,228,582	05-08-2001	Rodier, et al.	~
		6	6,395,306	05-28-2002	Cui, et al.	
		7	6,414,117	07-02-2002	Levinson, D. A.	
		8	6,465,185	10-15-2002	Goldfine, et al.	
		9	6,498,235	12-24-2002	Sheppard, et al.	-
	•	10	6,562,343	05-13-2003	Levinson, D. A.	
7		11	6,645,499	11-11-2003	Lal, et al.	
		12	6,730,502	05-04-2004	Van Hijum, et al.	_
		13	6,737,522	05-18-2004	Sundick, et al.	

		-	NON PATENT LITERATURE DOCUMENTS	,
Exam Initia		Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	τ¹
S	W	14	ALBERTS, et al. 1994. <i>Molecular Biology of the Cell, 3rd Edition</i> , pp. 403-404, 453. New York: Garland Publishing.	
		15	ALBERTS, et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , pp. 302, 363-364, 379, 435. New York: Garland Publishing.	_
		16	ALLMAN, et al. 1996. BCL-6 expression during B-cell activation. Blood, 87(12):5257-5268.	_
		17	CHEN, et al. 2002. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Molecular & Cellular Proteomics 1.4, 304-313.	(
		18	FU, et al. 1996. Translational regulation of human p53 gene expression. The EMBO Journal, Vol. 15, No. 16, pp. 4392-4401.	_
	·	19	GÖKMEN-POLAR, et al., February 2001, Elevated Protein Kinase C βII Is an Early Promotive Event in Colon Carcinogenesis, <i>Cancer Research</i> , Vol. 61, pp.1375-1381.	_
		20	GRIMALDI, et al. 1989. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. <i>Blood</i> , 73(8):2081-2085.	_

	\ \ \	1/	1 1	۱ا	<u> </u>		
Examiner Signature	Han	dra	\mathcal{N}	lean	Date Considered	1/6	106

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equiva	leni
------------------	------

* * * * * * * * * * * * * * * * * * * *		PTO/SB/08 Equivalent
117000	Application No.	10/063,718
INFORMATION DISCLOSURE	Filing Date	May 8, 2002
STATEMENT BY APPLICANT	First Named Inventor	Goddard, et al.
ATEMENT BY APPLICANT	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	· Claire M. Kaufman Sandra Weapof
SHEET 2 OF 3	Attorney Docket No.	GNE.3230R1C149

			NON PATENT LITERATURE DOCUMENTS	
Exami Initia		Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
54	2	21	GYGI, et al. Mar. 1999. Correlation between Protein and mRNA Abundance in Yeast. Molecular and Cellular Biology, 1720-1730.	-
		22	HANASH, S. 2003. Making sense of microarray data to classify cancer. <i>The Pharmacogenomics Journal</i> , 3:308-311.	
		23	HANASH, S. March 2005. Integrated global profiling of cancer. <i>Nature Reviews, Applied Proteomics Collection</i> , pp. 9-14.	_
		24	HANCOCK, W. S. 2004. Do We Have Enough Biomarkers? Journal of Proteome Research, 3(4):685.	
		25	HANNA, et al. Aug. 1999. HER-2/neu breast cancer predictive testing. <i>Pathology Associates Medical Laboratories</i> .	
		26	HAYNES, et al., 1998. Proteome analysis: Biological assay or data archive? <i>Electrophoresis</i> , Vol. 19, pp. 1862-1871.	-
·		27	HU, et al. 2003. Analysis of Genomic and Proteomic Data Using Advanced Literature Mining. Journal of Proteome Research, Vol. 2, pp. 405-412.	
		28	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. Cancer Research, 62:6240-6245.	_
		29	JANG A. Hill RP, Sept. 1997. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. <i>Clin. Exp. Metastasis</i> 15(5): pp. 469-483	_
		30	KONOPKA, et al. June 1986. Variable Expression of the Translocated c-abl Oncogene in Philadelphia-Chromosome-Positive B-Lymphoid Cell Lines from Chronic Myelogenous Leukemia Patients, National Academy of Sciences of the United States of America, Vol. 83, No. 11, pp. 4049-4052	_
		31	LEWIN, B. 1994. Oncogenes: Gene Expression and Cancer, Chap. 39, pp.1196-1201. Genes V. New York: Oxford University Press.	~
		32	LEWIN, B. 1997. Regulation of Transcription, Chap. 29, pp. 847-848. <i>Genes VI</i> . New York: Oxford University Press.	_
,		33	MEEKER, et al. 1990. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. <i>Blood</i> , 76(2):285-289.	
		34	MERIC, et al. 2002. Translation initiation in cancer: A novel target for therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
		35	OHARA, et al. 2001. Directional cDNA library construction assisted by the in vitro recombination reaction. <i>Nucleic Acids Research, Vol. 29, No e22</i> , pp.1-8.	
			ØRNTOFT, et al. 2002. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. <i>Molecular & Cellular Proteomics</i> , 1:37-45.	
		37	POLLACK, et al. 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. <i>PNAS</i> , 99(20):12963-12968.	<u>.</u>

	\bigcap	U	1	A		
Examiner Signature	Xar	NA	211	agen	Date Considered	1/6/06
					is in conformance with MPEP 609. h next communication to applicant.	Draw line through citation if not

T1 - Place a check mark in this area when an English language Translation is attached.

(O)		PTO/SB/08 Equivalent
्राणा से	Application No.	10/063,718
加 information disclosure	Filing Date	May 8, 2002
STATEMENT BY APPLICANT (Multiple sheets used when necessary)	First Named Inventor	Goddard, et al.
SIA CIVILIVI DI AFFLICANI	Art Unit	1647
(Multiple sheets used when necessary)	Examiner	Claire M. Kaufman Sondra Wegert
SHEET 3 OF 3	Attorney Docket No.	GNE.3230R1C149

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
NE	38	POWELL, et al. Oct. 1998. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype. <i>Pharmacogenetics</i> , Vol.5: pp. 411-421.)
	39	SINGLETON, et al. 1992. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol. Annu, 1(27):165-190.	·
	40	VALLEJO, et al. Dec. 2000. Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression. <i>Biochimie</i> 82(12): 1129-33.	-
	41	WANG, et al. 1996. mRNA Differential display: Application in the discovery of novel pharmacological targets. <i>Trends Pharmacol. Sci.</i> , 17(8):276-279.	1
	42	ZHIGANG, et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	(

1802095/jk 070605

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not ditation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/063,718
Filing Date	May 8, 2002
First Named Inventor	Goddard et al.
Art Unit	1647
Examiner	Sandra L. Wegert
Attorney Docket No.	GNE.3230R1C149

0¢7 1 1 2005

1	MERIE			FOREIGN PATI	ENT DOCUMENTS		
	Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	τ¹
	SW	1	WO 97/38085	10-16-1997	California Pacific Medical Center		

			NON PATENT LITERATURE DOCUMENTS	
Exan Initi		Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	• т¹
$\overline{\mathbb{Z}}$	W	2	ALBERTS, et al. 1994. Molecular Biology of the Cell, 3rd Edition, pp. 1216-1217. New York: Garland Publishing.	
		3	ANDERSON, et al. 1997. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis, 18:533-537.	
		4	FESSLER, et al. 2002. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. <i>The Journal of Biological Chemistry</i> , 277(35):31291-31302.	
		5	STRAUSBERG, et al., 2003, Accession No. AAH20905.1.	
		6	TOKUNAGA, et al. 2000. Application of quantitative RT-PCR using "TaqMan" technology to evaluate the expression of CK 18 mRNA in various cell lines. J. Exp. Clin. Cancer Res., 19(3):375-381.	

1941000\092005

Examiner Signature

Date Considered

6/06

*Examiner: Initial if reference considered, whether or not ditation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.